Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APDN 
Applied DNA Sciences Inc (APDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: APDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.1% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.83M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 1736424 | Beta 0.42 | 52 Weeks Range 1.45 - 450.00 | Updated Date 03/31/2025 |
52 Weeks Range 1.45 - 450.00 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -228.18% | Operating Margin (TTM) -247.7% |
Management Effectiveness
Return on Assets (TTM) -63.75% | Return on Equity (TTM) -103.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6744443 | Price to Sales(TTM) 0.49 |
Enterprise Value -6744443 | Price to Sales(TTM) 0.49 | ||
Enterprise Value to Revenue 0.88 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 1103770 | Shares Floating 959971 |
Shares Outstanding 1103770 | Shares Floating 959971 | ||
Percent Insiders 19.47 | Percent Institutions 26.9 |
Analyst Ratings
Rating 3 | Target Price 1.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Applied DNA Sciences Inc
Company Overview
History and Background
Applied DNA Sciences Inc. was founded in 1983. It initially focused on DNA-based security solutions and later expanded into biotherapeutic and diagnostic DNA production.
Core Business Areas
- DNA Manufacturing Services: Provides PCR-based DNA manufacturing for therapeutics, vaccines, and diagnostics.
- Supply Chain Security: Offers DNA tagging and authentication solutions to secure supply chains and combat counterfeiting.
- Molecular Tagging: Develops and markets DNA markers for product authentication and tracking.
Leadership and Structure
Dr. James Hayward serves as President and CEO. The company has a board of directors and is structured into operational divisions focused on its core business areas.
Top Products and Market Share
Key Offerings
- LinearDNA: A PCR-free DNA manufacturing platform. Revenue contribution is growing, but specific market share data is not publicly available. Competitors include GenScript Biotech, Twist Bioscience.
- SigNature DNA: A DNA-based marking system for product authentication and supply chain security. Market share is difficult to determine due to the fragmented nature of the anti-counterfeiting market. Competitors include Authentix, OpSec Security.
Market Dynamics
Industry Overview
The DNA manufacturing and supply chain security industries are experiencing growth driven by advancements in biotechnology, increasing concerns about counterfeiting, and the need for secure supply chains.
Positioning
Applied DNA Sciences Inc. is positioned as a provider of DNA-based solutions for various industries, with a focus on security and manufacturing. Its competitive advantage lies in its patented DNA tagging and authentication technologies.
Total Addressable Market (TAM)
The TAM for DNA-based security and biomanufacturing solutions is estimated to be in the billions of dollars. Applied DNA Sciences Inc. is targeting specific segments within this market, but its current revenue represents a small fraction of the total TAM.
Upturn SWOT Analysis
Strengths
- Patented DNA tagging and authentication technologies
- Expertise in DNA manufacturing
- Established presence in supply chain security
- Proprietary LinearDNA platform
Weaknesses
- Limited financial resources
- Small market share compared to larger competitors
- Dependence on a few key customers
- Historical unprofitability
Opportunities
- Growing demand for DNA-based therapeutics and vaccines
- Increasing adoption of supply chain security solutions
- Expansion into new markets and applications
- Partnerships and collaborations with other companies
Threats
- Competition from larger and more established companies
- Technological advancements that could render its technology obsolete
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- GHDX
- TWST
- ILMN
- TMO
Competitive Landscape
Applied DNA Sciences Inc. faces competition from larger, more established companies with greater financial resources and broader product portfolios. Its advantages lie in its proprietary technologies and specialized expertise.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent, with periods of rapid expansion followed by slowdowns.
Future Projections: Analyst estimates project continued revenue growth driven by the LinearDNA platform and increased adoption of its security solutions. However, profitability is uncertain.
Recent Initiatives: Recent initiatives include expanding the LinearDNA manufacturing capacity and forging partnerships to commercialize its products.
Summary
Applied DNA Sciences Inc. is a small cap biotech company with patented technology in DNA manufacturing and supply chain security. Its growth trajectory depends on successful commercialization of its LinearDNA platform and expansion of its security solutions. The company's persistent losses and small market share are concerns. Continued partnerships and strategic initiatives are crucial for future success. Limited cash position will need to be addressed.
Similar Companies
- TWST
- GHDX
- ILMN
- TMO
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Investor Presentations
- Analyst Reports (where available)
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and based on available information. Financial data is based on the most recent available reports and may be subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied DNA Sciences Inc
Exchange NASDAQ | Headquaters Stony Brook, NY, United States | ||
IPO Launch date 2003-07-15 | Chairman & CEO Dr. James A. Hayward Ph.D., Sc.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.adnas.com |
Full time employees 46 | Website https://www.adnas.com | ||
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.